BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2025.
World J Virol. Sep 25, 2025; 14(3): 107008
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.107008
Table 3 Predictors of sustained viral load suppression among people living with human immunodeficiency virus in Rwanda
Characteristics
Complete case analysis
Imputed datasets
BivariateMultivariableBivariateMultivariable
IRR (95%CI)
P value
aIRR (95%CI)
P value
IRR (95%CI)
P value
aIRR (95%CI)
P value
Age, year
    18-24Reference-Reference-Reference-Reference-
    25-341.10 (0.86-1.40)0.4550.99 (0.83-1.19)0.9441.10 (0.86-1.40)0.4551.09 (0.87-1.35)0.484
    35-441.03 (0.81-1.32)0.7920.94 (0.78-1.14)0.5401.03 (0.81-1.32)0.7921.03 (0.83-1.29)0.776
    45-541.20 (0.94-1.52)0.1481.12 (0.92-1.35)0.2511.20 (0.94-1.52)0.1481.22 (0.97-1.52)0.086
    ≥ 551.05 (0.81-1.37)0.6910.98 (0.80-1.22)0.8791.05 (0.81-1.37)0.6911.09 (0.85-1.36)0.492
Gender
    FemaleReference-Reference-Reference-Reference-
    Male0.95 (0.89-1.02)0.1390.96 (0.89-1.03)0.2300.95 (0.89-1.02)0.1390.95 (0.89-1.02)0.136
Education
    No educationReference-Reference-Reference-Reference-
    ≥ Primary1.08 (1.01-1.16)0.012a1.09 (1.01-1.17)0.031a1.09 (1.02-1.16)0.012a1.09 (1.02-1.16)0.012a
HIV status disclosed
    NoReference-Reference-Reference-Reference-
    Yes0.99 (0.93-1.05)0.7331.00 (0.94-1.09)0.8400.99 (0.93-1.05)0.7711.00 (0.94-1.06)0.952
Adherence
    < 90%Reference-Reference-Reference-Reference-
    ≥ 90%1.09 (1.00-1.20)0.050a1.05 (0.96-1.15)0.3091.06 (0.99-1.15)0.1111.04 (0.96-1.12)0.349
Advance HIV disease
    NoReference-Reference-Reference-Reference-
    Yes0.87 (0.78-0.97)0.014a0.88 (0.79-0.99)0.034a0.89 (0.81-0.98)0.020a0.89 (0.82-0.98)0.019a
Timing of ART initiation
    Before treat allReference-Reference-Reference-Reference-
    After treat all0.98 (0.92-1.04)0.5430.97 (0.90-1.05)0.4660.97 (0.92-1.04)0.4320.97 (0.91-1.04)0.385


Write to the Help Desk